Clinical Trials List
2021-12-31 - 2026-12-31
Phase III
Recruiting8
ICD-10N03.1
Chronic nephritic syndrome with focal and segmental glomerular lesions
ICD-10N03.3
Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis
ICD-9582.1
Chronic glomerulonephritis, with lesion of membranous glomerulonephritis
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 黃道民 Division of General Internal Medicine
- VIN-CENT Wu Division of General Internal Medicine
- 陳怡婷 Division of Family Medicine
- Yung-Ming Chen Division of General Internal Medicine
- 楊紹佑 Division of General Internal Medicine
- - - Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 高芷華 Division of Nephrology
- Mei-Yi Wu Division of Nephrology
- Li-Yee Hong Division of Nephrology
- Cai-Mei Zheng Division of Nephrology
- 林冠宏 Division of Nephrology
- Chia-Te Liao Division of Nephrology
- I-WEN WU Division of Nephrology
- YUNG-HO HSU Division of Nephrology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Hsi-Hsien Chen Division of Nephrology
- Te-Chao Fang Division of Nephrology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yi wen chiu Division of Nephrology
- 郭弘典 Division of Nephrology
- 林麗玫 Division of Nephrology
- 張哲銘 Division of Nephrology
- 李佳蓉 Division of Nephrology
- 張立昀 Division of Nephrology
- Hung-Chun CHEN Division of Nephrology
- 吳秉勳 Division of Nephrology
- 洪啟智 Division of Nephrology
- 郭美娟 Division of Nephrology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
32 participants
-
Global
286 participants
